摘要:
Objective To investigate the inhibitory effect of bicalutamide ( BIC) combined with paclitaxel (PTX) on the proliferation of androgen receptor (AR) -positive triple negative breast cancer MDA-MB-231 cells and its possible mechanism. Methods The CCK-8 kit was used to determine the effect of BIC (0. 1, 1. 0, 10. 0 μmol/L ) and PTX at different concentrations ( 0. 1, 1. 0, 10. 0, 100. 0, 1000. 0, 10 000. 0 nmol/L)in monotherapy or in sequential combination of both on the proliferation of MDA-MB-231 cells. Inhibition rate was compared using one-way analysis of variance. The pairwise comparison was performed using the LSD method. MDA-MB-231 cells were treated with 10 nmol/L PTX and 10 nmol/L DMSO respectively for 72 h. Three cell samples were taken in each group to analyze the relevant gene expression profiling in array using a bioinformatic method. The adjusted t test was used to screen out differential genes. Results After MDA-MB-231 cells were treated with different concentrations of BIC for 24, 48 and 72 h, respectively, the inhibition rates of MDA-MB-231 cells were statistically different at different time points (F=4. 124, 8. 189, 4. 139, P=0. 037, 0. 004, 0. 032). The inhibition rate of MDA-MB-231 cells reached the highest [(12. 9 ± 5. 5)% ] at 48 h after the treatment of 10. 0 μmol/L BIC. The inhibition rates of MDA-MB-231 cells were significantly different at different time points (F=8. 407, 47. 432, 14. 907, P<0. 001) after the treatment of PTX at different concentrations. The half inhibitory concentration (IC50) of PTX in MDA-MB-231 cells at 48 h was 5 380. 0 nmol/L. After 48 h treatment of 5 000. 0 nmol/L PTX alone or combined with 0. 1, 1. 0, 10. 0 μmol/L BIC, the inhibition rate of MDA-MB-231 cells was (53. 2 ± 2. 7)% , (53. 2 ± 3. 1)% , (51. 7 ± 3. 4)% , (51. 0 ± 2. 3)% in PTX monotherapy group and three experimental groups, respectively, indicating no significant difference (F=0. 831,P=0. 492). MDA-MB-231 cells were treated with sequential combination of 5 000. 0 nmol/L PTX and 10. 0 μmol/L BIC (PTX 24 h+BIC 24 h group,BIC 24 h+PTX 24 h group,PTX 48 h+BIC 24 h group,BIC 48h+PTX 24 h group), the monotherapy with 5 000. 0 nmol/L PTX ( PTX 48 h group) or 10. 0 μmo/L BIC (BIC 48 h group) and the synchronous combined therapy of PTX and BIC(PTX 48 h+BIC 48 h group), respectively. The result showed that there was a statistically significant difference in inhibition rate (F=241. 466, P<0. 001). The result of pairwise comparison showed that the inhibition rate in PTX 24 h+BIC 24 h group was (72. 9 ± 1. 9)% , significantly higher than (42. 9 ± 1. 7)% in BIC 24 h + PTX 24 h group (P<0. 001),(60. 9 ± 3. 7)% in PTX 48 h group(P<0. 001) and (60. 3 ± 4. 1)% in PTX 48 h +BIC 48 h group (P<0. 001). There was a significant difference in the expression of seven genes (EGR1, FST, FOS, IL8, IL6, RPL27A and CA2) between PTX-treated group and DMSO-treated group ( t= 18. 647, 10. 336, 10. 098, 9. 683, 9. 408, 9. 050, 8. 001, all P<0. 050 ) Conclusions Sequential administration of PTX and BIC can inhibit the proliferation of AR-positive triple negative breast cancer MDA-MB-231 cells more effectively compared with the monotherapy and other combination methods. The two drugs may have the synergistic effect.%目的 探讨比卡鲁胺(BIC)联合化疗药物紫杉醇( PTX)对雄激素受体( AR)阳性的三阴性乳腺癌MDA-MB-231细胞的增殖抑制作用及可能的作用机制.方法 采用CCK-8试剂盒观察不同浓度的BIC (0. 1、1. 0、10. 0 μmol/L)和PTX(0. 1、1. 0、10. 0、100. 0、1 000. 0、10 000. 0 nmol/L)以单药及不同联合给药方式处理后,对MDA-MB-231 细胞增殖的抑制作用.细胞增殖抑制率比较采用单因素方差分析.组间两两比较采用LSD法.选取10 nmol/L PTX及10 nmol/L DMSO分别处理MDA-MB-231 细胞样品(各3个)72 h,采用生物信息学方法分析样品的相关基因表达芯片数据,采用校正t检验筛选出差异基因.结果 使用不同浓度的BIC分别处理MDA-MB-231 细胞24、48、72 h后,各组MDA-MB-231细胞增殖抑制率在不同时间点差异均有统计学意义(F=4. 124、8. 189、4. 139, P=0. 037、0. 004、0. 032).BIC 10. 0 μmol/L 组MDA-MB-231 细胞增殖抑制率在48 h 最高,为(12. 9 ± 5. 5)% .不同浓度的PTX分别处理MDA-MB-231 细胞24、48、72 h后,不同浓度组MDA-MB-231 细胞增殖抑制率在不同时间点差异均有统计学意义(F=8. 407、47. 432、14. 907, P均<0. 001). PTX在48 h时对MDA-MB-231 细胞的半数抑制浓度(IC50)为5 380. 0 nmol/L. 5 000. 0 nmol/L PTX单药或联合不同浓度(0. 1、1. 0、10. 0 μmol/L)的BIC同时处理MDA-MB-231细胞48 h后,5 000. 0 nmol/L PTX单药处理组与3个实验组中细胞增殖抑制率分别为(53. 2±2. 7)% 、(53. 2±3. 1)% 、(51. 7±3. 4)% 、(51. 0±2. 3)% ,组间差异无统计学意义(F=0. 831,P=0. 492).采用5 000. 0 nmol/L PTX和10. 0 μmol/L BIC以不同的序贯方式联合给药处理MDA-MB-231 细胞(PTX 24 h +BIC 24 h 组、BIC 24 h +PTX 24 h 组、PTX 48 h +BIC 24 h 组、BIC 48 h+PTX 24 h 组),并用5 000. 0 nmol/L PTX(PTX 48 h组)和10. 0 μmol/L BIC(BIC 48 h组)单药处理及同时联合给药(PTX 48 h+ BIC 48 h 组)分别处理MDA-MB-231 细胞后,各组间细胞增殖抑制率差异有统计学意义(F=241. 466,P<0. 001).其中,两两比较结果显示,PTX 24 h+BIC 24 h组细胞增殖抑制率为(72. 9±1. 9)% ,高于BIC 24 h +PTX 24 h组的(42. 9±1. 7)% (P<0. 001),PTX 48 h组的(60. 9±3. 7)% (P<0. 001)和PTX 48 h +BIC 48 h组的(60. 3±4. 1)% (P<0. 001). PTX处理组中有EGR1、FST、FOS、IL8、IL6、RPL27A及CA2 7 个基因的表达量与DMSO处理组比较,差异均有统计学意义( t=18. 647、10. 336、10. 098、9. 683、9. 408、9. 050、8. 001,P均<0. 050).结论 通过先PTX 再BIC 的序贯联合给药方式较单药及其他联合给药方式能够更有效抑制AR 阳性三阴性乳腺癌细胞MDA-MB-231 的增殖,两者间可能存在协同作用.